The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease DOI Creative Commons
Ola Bratt, Stefan Carlsson, Per Fransson

и другие.

Scandinavian Journal of Urology, Год журнала: 2022, Номер 56(4), С. 265 - 273

Опубликована: Июль 4, 2022

There is now an unprecedented amount of evidence to consider when revising prostate cancer guidelines. We believe that there a value in publishing summaries national clinical guidelines English for others read and comment on.This part 1 summary the Swedish were published June 2022. It covers early detection, diagnostics, staging, patient support management non-metastatic disease. Part 2 recurrence after local treatment metastatic disease.The 2022 include several new recommendations: rectal iodine-povidone reduce post-biopsy infections, external beam radiation with focal boost tumour, use pre-rectal spacer side effects radiotherapy some expert centres, 6 months' concomitant adjuvant rather than neoadjuvant hormonal together unfavourable intermediate high-risk disease, abiraterone plus prednisolone GnRH agonist subgroup men very The differ from European by having more restrictive recommendations regarding genetic testing pelvic lymph node dissection, risk group classification, recommending ultra-hypofractionated (7 fractions) selected cancers, not any favourable intermediate-risk bicalutamide monotherapy instead groups.The

Язык: Английский

2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review DOI Creative Commons
Oskar Bergengren, Kelly Pekala, Konstantina Matsoukas

и другие.

European Urology, Год журнала: 2023, Номер 84(2), С. 191 - 206

Опубликована: Май 17, 2023

Язык: Английский

Процитировано

370
Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives DOI Open Access
Felice Crocetto, Gianluca Russo, Erika Di Zazzo

и другие.

Cancers, Год журнала: 2022, Номер 14(13), С. 3272 - 3272

Опубликована: Июль 4, 2022

Although appreciable attempts in screening and diagnostic approaches have been achieved, prostate cancer (PCa) remains a widespread malignancy, representing the second leading cause of cancer-related death men. Drugs currently used PCa therapy initially show potent anti-tumor effect, but frequently induce resistance progresses toward metastatic castration-resistant forms (mCRPC), virtually incurable. Liquid biopsy has emerged as an attractive promising strategy complementary to invasive tissue guide diagnosis treatment. shows ability represent tumor microenvironment, allow comprehensive information follow-up progression tumor, enabling development different treatment strategies well permitting monitoring response. biopsy, indeed, is endowed with significant potential modify management. Several blood biomarkers could be analyzed for diagnostic, prognostic predictive purposes, including circulating cells (CTCs), extracellular vesicles (EVs), DNA (ctDNA) RNA (ctRNA). In addition, several other body fluids may adopted (i.e., urine, sperm, etc.) beyond blood. This review dissects recent advancements future perspectives liquid biopsies, highlighting their strength weaknesses

Язык: Английский

Процитировано

80
Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis DOI Creative Commons
Cristina V. Berenguer,

Ferdinando Pereira,

José S. Câmara

и другие.

Current Oncology, Год журнала: 2023, Номер 30(2), С. 2300 - 2321

Опубликована: Фев. 15, 2023

Prostate cancer (PCa) is the most frequently occurring type of malignant tumor and a leading cause oncological death in men. PCa very heterogeneous terms grade, phenotypes, genetics, displaying complex features. This often has indolent growth, not compromising patient’s quality life, while its more aggressive forms can manifest rapid growth with progression to adjacent organs spread lymph nodes bones. Nevertheless, overtreatment patients leads important physical, mental, economic burdens, which be avoided careful monitoring. Early detection, even cases locally advanced metastatic tumors, provides higher chance cure, thus go through less treatments fewer side effects. Furthermore, it offer knowledge about how modifiable risk factors an effective method for reducing risk. Innovations diagnostics therapy are still required overcome some limitations current screening techniques, specificity sensitivity. In this context, review brief overview statistics, reporting incidence mortality rates worldwide, factors, emerging strategies.

Язык: Английский

Процитировано

59
Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM DOI
Sai Tian, Jinbo Zhang,

Shunling Yuan

и другие.

Briefings in Bioinformatics, Год журнала: 2023, Номер 24(2)

Опубликована: Янв. 31, 2023

With the emergence of high-throughput technologies, computational screening based on gene expression profiles has become one most effective methods for drug discovery. More importantly, profile-based approaches remarkably enhance novel drug-disease pair discovery without relying drug- or disease-specific prior knowledge, which been widely used in modern medicine. However, systematic active ingredients traditional Chinese medicine (TCM) scarcely performed due to inadequate pharmacotranscriptomic data. Here, we develop largest-to-date online TCM ingredients-based platform integrated (ITCM) ingredients. First, unified experiments and constructed largest data repository 496 representative ingredients, was five times larger than previous built by our team. The transcriptome-based multi-scale analysis also elucidate their mechanism. Then, developed six state-of-art signature search screen determine optimal size all methods. Moreover, them into a strategy, TCM-Query, identify potential special disease. In addition, comprehensively collected TCM-related resource literature mining. Finally, applied ITCM an ingredient bavachinin, two diseases, including prostate cancer COVID-19, demonstrate power aimed explore boost studies pharmacological action is available at http://itcm.biotcm.net.

Язык: Английский

Процитировано

57
Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer DOI
Ying Yu,

Xing Huang,

Chaoqi Liang

и другие.

European Journal of Pharmacology, Год журнала: 2023, Номер 957, С. 176007 - 176007

Опубликована: Авг. 21, 2023

Язык: Английский

Процитировано

51
Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study DOI Creative Commons
Weiyu Zhang, Guiying Cao, Feng Wu

и другие.

Journal of Epidemiology and Global Health, Год журнала: 2023, Номер 13(3), С. 407 - 421

Опубликована: Май 6, 2023

Both the morbidity and mortality of prostate cancer are increasing worldwide. Updated evaluations burden its global, regional national patterns essential for formulating effective preventive strategies. To investigate incidence, mortality, disability-adjusted life years (DALYs) between 1990 2019 to facilitate measures control planning. Annual incident cases, deaths, DALYs, age-standardized incidence rates (ASIRs), (ASMRs), DALYs (ASDRs) were derived from Global Burden Diseases study 2019. Percentage changes in deaths estimated annual percentage (EAPCs) ASIRs, ASMRs ASDRs calculated quantify temporal trends. Correlations EAPCs socio-demographic index (SDI) universal health coverage (UHCI) evaluated by Pearson correlation analyses. Globally, number increased 116.11%, 108.94%, 98.25% 2019, respectively. The ASIR an average 0.26% (95% CI: 0.14%, 0.37%) per year while ASMR ASDR decreased - 0.75% 0.84%, 0.67%) 0.71% 0.78%, 0.63%) this period, Epidemic trends burdens not uniform throughout different groups SDI or geography. varied across regions, with trend ASIR, ASMR, low low-middle regions A significant positive EAPC UHCI was observed countries a < 70 (ρ = 0.37, p 0.001). Prostate remains major global due increase past three decades. These increases likely continue as population ages, which indicates potential talent gap trained healthcare workforce. diversity development models implies importance specific local strategies tailored each country's risk factor profile. Prevention, early detection more treatment essential.

Язык: Английский

Процитировано

49
A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers DOI Creative Commons

Ehsan Zolfi,

Farhood Khaleghi mehr,

Nikoo Emtiazi

и другие.

Virology Journal, Год журнала: 2025, Номер 22(1)

Опубликована: Фев. 28, 2025

Direct skin-to-skin contact during intimate sexual with a human papillomavirus (HPV)-positive individual is often the cause of HPV infection. In addition, many studies have been written up to date that look at role in growth other types tumors. Not all urological cancers are associated HPV. However, penile cancer (PC) caused by HPV, especially high-risk types. HPV-16 has most frequent (68.3%), followed HPV-6 (8.1%) and HPV-18 (6.9%). An increased risk getting certain urinary like prostate, bladder, testicular, kidney also linked these infections. Additionally, may play part continuous inflammation progression different organs tissues. So, making vaccine programs available more people male sex around world could significantly lower number The critical effects on urologic (UCs), such as penile, cancer, importance vaccination seen this study.

Язык: Английский

Процитировано

3
Long-term exposure to ambient air pollutants and risk of prostate cancer: a prospective cohort study DOI

Yu Chen,

Siru Yang,

Jiahao Lin

и другие.

Environmental Research, Год журнала: 2025, Номер unknown, С. 121020 - 121020

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

2
Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship DOI
Roberta Modica, Elio Benevento, Annamaria Colao

и другие.

Journal of Endocrinological Investigation, Год журнала: 2022, Номер 46(4), С. 667 - 677

Опубликована: Дек. 16, 2022

Язык: Английский

Процитировано

49
The Role of Isoflavones in the Prevention of Breast Cancer and Prostate Cancer DOI Creative Commons
T. Pejcic, Milica Zeković, Uroš Bumbaširević

и другие.

Antioxidants, Год журнала: 2023, Номер 12(2), С. 368 - 368

Опубликована: Фев. 3, 2023

This narrative review summarizes epidemiological studies on breast cancer and prostate with an overview of their global incidence distribution to investigate the relationship between these diseases diet. The biological properties, mechanisms action, available data supporting potential role isoflavones in prevention are discussed. Studies evaluating effects tissue cultures normal malignant cells, as well current body research regarding attained through multiple modifications cellular molecular signaling pathways control oxidative stress, summarized. Furthermore, this compiles literature sources reporting following: (1) levels estrogen tissue; (2) organs European Asian populations; (3) average concentrations secretion (milk semen). Finally, particular emphasis is placed investigating effect tissues via receptors (ER).

Язык: Английский

Процитировано

37